-
1
-
-
1542378867
-
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose
-
Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
-
(2004)
Ann Intern Med
, vol.140
, pp. 346-355
-
-
Hadziyannis, S.J.1
Sette Jr., H.2
Morgan, T.R.3
-
2
-
-
0037179698
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
-
Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
-
(2002)
N Engl J Med
, vol.347
, pp. 975-982
-
-
Fried, M.W.1
Shiffman, M.L.2
Reddy, K.R.3
-
3
-
-
70349533037
-
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
-
Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109.
-
(2009)
Nat Genet
, vol.41
, pp. 1105-1109
-
-
Tanaka, Y.1
Nishida, N.2
Sugiyama, M.3
-
4
-
-
79952308232
-
Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C
-
Villa E, Karampatou A, Cammà C, et al. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology 2011; 140:818-829.
-
(2011)
Gastroenterology
, vol.140
, pp. 818-829
-
-
Villa, E.1
Karampatou, A.2
Cammà, C.3
-
5
-
-
78751508078
-
Hepatitis C pharmacogenetics: State of the art in 2010
-
Afdhal N, McHutchison J, Zeuzem S, et al. Hepatitis C pharmacogenetics: state of the art in 2010; Hepatology 2011; 53:336-345.
-
(2011)
Hepatology
, vol.53
, pp. 336-345
-
-
Afdhal, N.1
McHutchison, J.2
Zeuzem, S.3
-
6
-
-
34247539146
-
The impact of insulin resistance, serum adipocytokines and visceral obesity on liver steatosis and fibrosis in patients with chronic hepatitis C
-
Lo Iacono O, Venezia G, Petta S, et al. The impact of insulin resistance, serum adipocytokines and visceral obesity on liver steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2007; 25:1181-1191.
-
(2007)
Aliment Pharmacol Ther
, vol.25
, pp. 1181-1191
-
-
Lo Iacono, O.1
Venezia, G.2
Petta, S.3
-
7
-
-
69849109303
-
Time course of insulin resistance during antiviral therapy in non-diabetic, noncirrhotic patients with genotype 1 HCV infection
-
Petta S, Cammà C, Di Marco V, et al. Time course of insulin resistance during antiviral therapy in non-diabetic, noncirrhotic patients with genotype 1 HCV infection. Antivir Ther 2009; 14:631-639.
-
(2009)
Antivir Ther
, vol.14
, pp. 631-639
-
-
Petta, S.1
Cammà, C.2
Di Marco, V.3
-
8
-
-
15744381704
-
Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients
-
Romero-Gómez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128:636-641.
-
(2005)
Gastroenterology
, vol.128
, pp. 636-641
-
-
Romero-Gómez, M.1
Del Mar Viloria, M.2
Andrade, R.J.3
-
9
-
-
0041822106
-
Early virologic response to treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C
-
Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38:645-652.
-
(2003)
Hepatology
, vol.38
, pp. 645-652
-
-
Davis, G.L.1
Wong, J.B.2
McHutchison, J.G.3
Manns, M.P.4
Harvey, J.5
Albrecht, J.6
-
10
-
-
23444460553
-
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ ribavirin
-
Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ ribavirin. J Hepatol 2005; 43:425-433.
-
(2005)
J Hepatol
, vol.43
, pp. 425-433
-
-
Ferenci, P.1
Fried, M.W.2
Shiffman, M.L.3
-
11
-
-
28844451934
-
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
-
Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44:97-103.
-
(2006)
J Hepatol
, vol.44
, pp. 97-103
-
-
Zeuzem, S.1
Buti, M.2
Ferenci, P.3
-
12
-
-
48749099989
-
Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response
-
Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135:451-458.
-
(2008)
Gastroenterology
, vol.135
, pp. 451-458
-
-
Ferenci, P.1
Laferl, H.2
Scherzer, T.M.3
-
13
-
-
46249114151
-
Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial
-
Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47:1884-1893.
-
(2008)
Hepatology
, vol.47
, pp. 1884-1893
-
-
Yu, M.L.1
Dai, C.Y.2
Huang, J.F.3
-
14
-
-
84984562129
-
Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: A multicenter, randomized controlled trial
-
Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47:1260-1269.
-
(2008)
Clin Infect Dis
, vol.47
, pp. 1260-1269
-
-
Liu, C.H.1
Liu, C.J.2
Lin, C.L.3
-
15
-
-
38649090347
-
Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial
-
Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008; 47:43-50.
-
(2008)
Hepatology
, vol.47
, pp. 43-50
-
-
Mangia, A.1
Minerva, N.2
Bacca, D.3
-
16
-
-
68949183162
-
Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients
-
Berg T, Weich V, Teuber G, et al. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology 2009; 50:369-377.
-
(2009)
Hepatology
, vol.50
, pp. 369-377
-
-
Berg, T.1
Weich, V.2
Teuber, G.3
-
17
-
-
70349292099
-
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
-
Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
-
(2009)
Nature
, vol.461
, pp. 399-401
-
-
Ge, D.1
Fellay, J.2
Thompson, A.J.3
-
18
-
-
70349548852
-
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
-
Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41:1100-1104.
-
(2009)
Nat Genet
, vol.41
, pp. 1100-1104
-
-
Suppiah, V.1
Moldovan, M.2
Ahlenstiel, G.3
-
19
-
-
70349533037
-
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
-
Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109.
-
(2009)
Nat Genet
, vol.41
, pp. 1105-1109
-
-
Tanaka, Y.1
Nishida, N.2
Sugiyama, M.3
-
20
-
-
77949831342
-
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: A genome-wide association study
-
Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138:1338-1345.
-
(2010)
Gastroenterology
, vol.138
, pp. 1338-1345
-
-
Rauch, A.1
Kutalik, Z.2
Descombes, P.3
-
21
-
-
77953881002
-
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus
-
Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139:120-129.
-
(2010)
Gastroenterology
, vol.139
, pp. 120-129
-
-
Thompson, A.J.1
Muir, A.J.2
Sulkowski, M.S.3
-
22
-
-
33646590308
-
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy
-
Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43:954-960.
-
(2006)
Hepatology
, vol.43
, pp. 954-960
-
-
Jensen, D.M.1
Morgan, T.R.2
Marcellin, P.3
-
23
-
-
71549129264
-
Insulin resistance predicts rapid virological response in non-diabetic, noncirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin
-
Grasso A, Malfatti F, De Leo PD, et al. Insulin resistance predicts rapid virological response in non-diabetic, noncirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J Hepatol 2009; 51:984-990.
-
(2009)
J Hepatol
, vol.51
, pp. 984-990
-
-
Grasso, A.1
Malfatti, F.2
De Leo, P.D.3
-
24
-
-
17144399925
-
Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection
-
Schiefke I, Fach A, Wiedmann M, et al. Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol 2005; 11:1843-1847.
-
(2005)
World J Gastroenterol
, vol.11
, pp. 1843-1847
-
-
Schiefke, I.1
Fach, A.2
Wiedmann, M.3
-
25
-
-
0034796623
-
Calcium-parathyroid hormone-vitamin D axis and metabolic bone disease in chronic viral liver disease
-
Duarte MP, Farias ML, Coelho HS, et al. Calcium-parathyroid hormone-vitamin D axis and metabolic bone disease in chronic viral liver disease. J Gastroenterol Hepatol 2001; 16:1022-1027.
-
(2001)
J Gastroenterol Hepatol
, vol.16
, pp. 1022-1027
-
-
Duarte, M.P.1
Farias, M.L.2
Coelho, H.S.3
-
26
-
-
0030012271
-
Metabolic bone disease of liver cirrhosis: Is it parallel to the clinical severity of cirrhosis?
-
Chen CC, Wang SS, Jeng FS, Lee SD. Metabolic bone disease of liver cirrhosis: is it parallel to the clinical severity of cirrhosis? J Gastroenterol Hepatol 1996; 11:417-421.
-
(1996)
J Gastroenterol Hepatol
, vol.11
, pp. 417-421
-
-
Chen, C.C.1
Wang, S.S.2
Jeng, F.S.3
Lee, S.D.4
-
27
-
-
34147144615
-
Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease
-
Fisher L, Fisher A. Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin Gastroenterol Hepatol 2007; 5:513-520.
-
(2007)
Clin Gastroenterol Hepatol
, vol.5
, pp. 513-520
-
-
Fisher, L.1
Fisher, A.2
-
28
-
-
77950624679
-
Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C
-
Petta S, Cammà C, Scazzone C, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010; 51:1158-1167.
-
(2010)
Hepatology
, vol.51
, pp. 1158-1167
-
-
Petta, S.1
Cammà, C.2
Scazzone, C.3
-
29
-
-
16544367410
-
Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system
-
Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004; 80 Suppl 6:1717S-1720S.
-
(2004)
Am J Clin Nutr
, vol.80
, Issue.SUPPL. 6
-
-
Cantorna, M.T.1
Zhu, Y.2
Froicu, M.3
Wittke, A.4
-
30
-
-
77949873898
-
Vitamin D controls T cell antigen receptor signaling and activation of human T cells
-
von Essen MR, Kongsbak M, Schjerling P, Olgaard K, Odum N, Geisler C. Vitamin D controls T cell antigen receptor signaling and activation of human T cells. Nat Immunol 2010; 11:344-349.
-
(2010)
Nat Immunol
, vol.11
, pp. 344-349
-
-
Von Essen, M.R.1
Kongsbak, M.2
Schjerling, P.3
Olgaard, K.4
Odum, N.5
Geisler, C.6
-
31
-
-
84865781704
-
The beneficial effect of vitamin D combined with Peg interferon and ribavirin for chronic HCV infection
-
Abu-Mouch S, Fireman Z, Jarchovsky J, Assy N. The beneficial effect of vitamin D combined with Peg interferon and ribavirin for chronic HCV infection. J Hepatol 2010; 52 Suppl 1:55.
-
(2010)
J Hepatol
, vol.52
, Issue.SUPPL. 1
, pp. 55
-
-
Abu-Mouch, S.1
Fireman, Z.2
Jarchovsky, J.3
Assy, N.4
-
32
-
-
77953207214
-
Review article: Specifically targeted anti-viral therapy for hepatitis C - A new era in therapy
-
Lange CM, Sarrazin C, Zeuzem S. Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy. Aliment Pharmacol Ther 2010; 32:14-28.
-
(2010)
Aliment Pharmacol Ther
, vol.32
, pp. 14-28
-
-
Lange, C.M.1
Sarrazin, C.2
Zeuzem, S.3
-
33
-
-
17144469684
-
Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. American Diabetes Association: Clinical Practice Recommendations 2000 Committee Report
-
American Diabetes Association
-
American Diabetes Association. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. American Diabetes Association: Clinical Practice Recommendations 2000 Committee Report. Diabetes Care 2000; 23 Suppl 1:S4-S19.
-
(2000)
Diabetes Care
, vol.23
, Issue.SUPPL. 1
-
-
-
34
-
-
0021813187
-
Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
-
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28:412-419.
-
(1985)
Diabetologia
, vol.28
, pp. 412-419
-
-
Matthews, D.R.1
Hosker, J.P.2
Rudenski, A.S.3
Naylor, B.A.4
Treacher, D.F.5
Turner, R.C.6
-
35
-
-
0042671303
-
Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: The smaller the sample, the milder the disease
-
Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39:239-244.
-
(2003)
J Hepatol
, vol.39
, pp. 239-244
-
-
Colloredo, G.1
Guido, M.2
Sonzogni, A.3
Leandro, G.4
-
36
-
-
0026072529
-
Classification of chronic viral hepatitis: A need for reassessment
-
Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13:372-374.
-
(1991)
J Hepatol
, vol.13
, pp. 372-374
-
-
Scheuer, P.J.1
-
37
-
-
0033406371
-
EASL International Consensus Conference on Hepatitis C, Paris, 26-27 February 1999 Consensus Statement
-
EASL International Consensus Conference on Hepatitis C, Paris, 26-27 February 1999 Consensus Statement. J Hepatol 1999 Suppl 1; 31:S3-S8.
-
(1999)
J Hepatol
, vol.31
, Issue.SUPPL. 1
-
-
-
38
-
-
0003514370
-
SAS/STAT software: Changes and enhancement
-
release 6.07. Cary, NC: SAS Institute, Inc.
-
SAS Technical Report, SAS/STAT software: changes and enhancement, release 6.07. Cary, NC: SAS Institute, Inc. 1992.
-
(1992)
SAS Technical Report
-
-
-
39
-
-
61849096685
-
Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: Looking to the future
-
Cammà C, Petta S. Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: looking to the future. J Hepatol 2009; 50:648-651.
-
(2009)
J Hepatol
, vol.50
, pp. 648-651
-
-
Cammà, C.1
Petta, S.2
|